{"id":4414,"date":"2024-01-16T01:12:00","date_gmt":"2024-01-16T01:12:00","guid":{"rendered":"https:\/\/economicherald.net\/?p=4414"},"modified":"2024-01-16T01:12:00","modified_gmt":"2024-01-16T01:12:00","slug":"asx-health-stocks-immuron-chalks-up-record-half-for-travelers-diarrhoea-medicine-travelan","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=4414","title":{"rendered":"ASX Health Stocks: Immuron chalks up record half for travelers\u2019 diarrhoea medicine, Travelan"},"content":{"rendered":"<p>Immuron\u2019s record half yearly sales of Travelan<br \/>\nHeraMED (ASX:HMD) to undergo maternity care pilot\u00a0 program in South Australia<br \/>\nPharmAust partners with US-based Berry Consultants as it prepare for FDA engagement<\/p>\n<p>\u00a0<\/p>\n<h2>Immuron\u2019s record half year<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/immuron-imc\/\">Immuron\u00a0(ASX:IMC)<\/a><\/strong> rose by almost 3% this morning after reporting <strong>record half yearly sales<\/strong> for its flagship product, <strong>Travelan<\/strong>.<\/p>\n<p>For H1 FY24, sales of Travelan increased to $1.85m, compared to $1.05m in the pcp. The figure was also 132% higher than the pre-pandemic peak period of H1, FY20.<\/p>\n<p>This increase partially reflects the three months (May, June, July) of back orders accrued while the company awaited GMP clearance from the TGA.<\/p>\n<p>Travelan is an orally administered immunotherapy that reduces the likelihood of contracting travelers\u2019 diarrhoea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.<\/p>\n<p>In the US, sales of Travelan for H1 FY24 were $482k, compared to $295k in H1 FY23.<\/p>\n<p>Immuron previously reported that it had shipped inventory to Amazon for launch in US. The Amazon launch continues to progress well with sales ahead of budget.<\/p>\n<p>As we are now entering the low travel season in US, Immuron anticipates sales to grow strongly closer to the peak spring\/summer travel period.<\/p>\n<p>\u00a0<\/p>\n<h2>HeraMed\u2019s pilot program in South Australia<\/h2>\n<p>The maternity care health tech company, <strong><a href=\"https:\/\/stockhead.com.au\/company\/heramed-hmd\/\">HeraMED\u00a0(ASX:HMD)<\/a><\/strong>, announced a strategic collaboration agreement with <strong>South Australia\u2019s GPEx<\/strong>, an organisation that delivers solutions for primary care, including\u00a0 GP shared care programs and clinical trials.<\/p>\n<p>GPEx and HeraMED will be undertaking a pilot program to better understand how the <strong>HeraCARE platform<\/strong> can benefit pregnant mothers and the health industry, in regional and remote South Australia.<\/p>\n<p>Under the terms, both companies will evaluate the deployment of the HeraCARE digital monitoring and management platform in high-risk pregnancies in regional and remote South Australia.<\/p>\n<p>The aim is to ultimately improve outcomes, decrease face-to-face antenatal visits, and ease the burden on the health system.<\/p>\n<p>The HeraCARE system allows expectant mothers to measure vitals at home via a mobile app and several smart connected devices, including a foetal heart rate monitor, blood pressure and glucometer.<\/p>\n<p>Doctors could then remotely monitor the mother and baby via a dashboard, identifying early complications and providing increased peace of mind during pregnancy.<\/p>\n<p>\u00a0<\/p>\n<h2>PharmAust engages FDA specialist, Berry Consultants<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/pharmaust-paa\/\">PharmAust\u00a0(ASX:PAA)<\/a><\/strong> meanwhile has partnered with leading MND\/ALS clinical study design and statistical analysis specialists, <strong>Berry Consultants<\/strong>.<\/p>\n<p>US-based Berry Consultants has a strong track record in clinical trial design and experience with the FDA.<\/p>\n<p>Their resume includes participation in the advisory committee meeting for the recent US FDA accelerated approval of <em>Amylyx Pharmaceutical\u2019s Relyvrio <\/em>for MND\/ALS. They\u2019ve also been integral to the <em>Healey ALS Platform Trial.<\/em><\/p>\n<p>Under the partnership deal, Berry Consultants will oversee the design of PharmAust\u2019s adaptive Phase 2\/3 study to best position monepantel for FDA approval for the treatment of MND\/ALS.<\/p>\n<p>\u00a0<\/p>\n<p class=\"p1\"><em>At Stockhead we tell it like it is. While PharmAust is a Stockhead advertiser, it did not sponsor this article.<\/em><\/p>\n<p><span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-immuron-chalks-up-record-half-for-travelers-diarrhoea-medicine-travelan\/\">ASX Health Stocks: Immuron chalks up record half for travelers\u2019 diarrhoea medicine, Travelan<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Immuron\u2019s record half yearly sales of Travelan HeraMED (ASX:HMD) to undergo maternity care pilot\u00a0 program in South Australia PharmAust partners with US-based Berry Consultants as <a href=\"https:\/\/economicherald.net\/?p=4414\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":4415,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-4414","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: Immuron chalks up record half for travelers\u2019 diarrhoea medicine, Travelan - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=4414\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Immuron chalks up record half for travelers\u2019 diarrhoea medicine, Travelan - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Immuron\u2019s record half yearly sales of Travelan HeraMED (ASX:HMD) to undergo maternity care pilot\u00a0 program in South Australia PharmAust partners with US-based Berry Consultants as [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=4414\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-16T01:12:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/01\/Immuron-reveals-record-half-yearly-sales-of-Travelan.-Picture-Getty-lt4RjJ.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=4414#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=4414\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Immuron chalks up record half for travelers\u2019 diarrhoea medicine, Travelan\",\"datePublished\":\"2024-01-16T01:12:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=4414\"},\"wordCount\":533,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=4414#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Immuron-reveals-record-half-yearly-sales-of-Travelan.-Picture-Getty-lt4RjJ.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=4414#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=4414\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=4414\",\"name\":\"ASX Health Stocks: Immuron chalks up record half for travelers\u2019 diarrhoea medicine, Travelan - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=4414#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=4414#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Immuron-reveals-record-half-yearly-sales-of-Travelan.-Picture-Getty-lt4RjJ.jpeg\",\"datePublished\":\"2024-01-16T01:12:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=4414#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=4414\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=4414#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Immuron-reveals-record-half-yearly-sales-of-Travelan.-Picture-Getty-lt4RjJ.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Immuron-reveals-record-half-yearly-sales-of-Travelan.-Picture-Getty-lt4RjJ.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=4414#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Immuron chalks up record half for travelers\u2019 diarrhoea medicine, Travelan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Immuron chalks up record half for travelers\u2019 diarrhoea medicine, Travelan - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=4414","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Immuron chalks up record half for travelers\u2019 diarrhoea medicine, Travelan - Economic Herald","og_description":"Immuron\u2019s record half yearly sales of Travelan HeraMED (ASX:HMD) to undergo maternity care pilot\u00a0 program in South Australia PharmAust partners with US-based Berry Consultants as [more...]","og_url":"https:\/\/economicherald.net\/?p=4414","og_site_name":"Economic Herald","article_published_time":"2024-01-16T01:12:00+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/01\/Immuron-reveals-record-half-yearly-sales-of-Travelan.-Picture-Getty-lt4RjJ.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=4414#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=4414"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Immuron chalks up record half for travelers\u2019 diarrhoea medicine, Travelan","datePublished":"2024-01-16T01:12:00+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=4414"},"wordCount":533,"commentCount":0,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=4414#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/01\/Immuron-reveals-record-half-yearly-sales-of-Travelan.-Picture-Getty-lt4RjJ.jpeg","articleSection":["Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/economicherald.net\/?p=4414#respond"]}]},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=4414","url":"https:\/\/economicherald.net\/?p=4414","name":"ASX Health Stocks: Immuron chalks up record half for travelers\u2019 diarrhoea medicine, Travelan - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=4414#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=4414#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/01\/Immuron-reveals-record-half-yearly-sales-of-Travelan.-Picture-Getty-lt4RjJ.jpeg","datePublished":"2024-01-16T01:12:00+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=4414#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=4414"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=4414#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/01\/Immuron-reveals-record-half-yearly-sales-of-Travelan.-Picture-Getty-lt4RjJ.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/01\/Immuron-reveals-record-half-yearly-sales-of-Travelan.-Picture-Getty-lt4RjJ.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=4414#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Immuron chalks up record half for travelers\u2019 diarrhoea medicine, Travelan"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/4414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4414"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/4414\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/4415"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}